FDA Approves Strattera

Eli Lilly and Company announced today that the FDA has approved Strattera for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant drug designed to treat ADHD in children, adolescents and adults. Unlike other ADD and ADHD medications such as Adderall and Ritalin, ...